Watson has high hopes for Stellar’s Uracyst drug
March 31, 2010 by leonardzehr · Leave a Comment
Watson Pharmaceuticals (NYSE:WPI) CEO, Paul Bisaro, painted a rosy picture of how Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug, which is indicated to treat interstitial cystitis, fills out its urology strategy. According to a presentation at a healthcare conference sponsored by Barclays Capital, Mr. Bisaro said that Watson’s strategy is based on the 10 most common [...]
Listen to BioTuesdays 
